KENGREXAL
Google image searchProduct monograph
Active ingredient
cangrelor (cangrelor tetrasodium), 50 MG/VIAL
DIN: 02534622
Dosage form(s): POWDER FOR SOLUTION
Route(s) of administration: INTRAVENOUS
Schedule: Prescription
Company: CHIESI FARMACEUTICI S.P.A.
Date: 30-NOV-2023
ATC:
- B01 — ANTITHROMBOTIC AGENTS (ATC, ATC/DDD, )
- B01A — ANTITHROMBOTIC AGENTS (ATC, ATC/DDD)
- B01AC — Platelet aggregation inhibitors excl. heparin (ATC, ATC/DDD)
- B01AC25 — CANGRELOR (ATC/DDD)
Reference brand drug: Kengrexal
Pharmaceutical standard: MFR
